Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
J Med Virol ; 95(12): e29321, 2023 12.
Article in English | MEDLINE | ID: mdl-38108193

ABSTRACT

In May 2019, a measles outbreak occurred in the French subregion of Loire-Atlantique, particularly affecting Roma settlements. Various obstacles hindered the implementation of postexposure measures among Roma population, resulting in the spread of the cases to other settlements. Suspected cases of measles were immediately investigated and concerned settlements were visited for measles-mumps-rubella (MMR) vaccination. From July 1 to September 3, 2019, a first and then a second Health Reserve team helped for vaccination on the affected and then also the measles-free settlements. Vaccination uptake was monitored with the use of the department's vaccination center immunization registry. Genotyping of selected samples was performed for comparison with viruses circulating at the same time in France and Romania. As of September 16 2019, 109 cases of measles were confirmed among Roma population, including 99 (91%) children under 15 years. Of the 85 people eligible for vaccination, 60 (71%) had not been vaccinated and 23 (27%) had an unknown vaccination status. Sequence comparison revealed that 28/29 sequenced D8 strains were 100% identical to the strain responsible for a large number of cases throughout France in 2019, and to two sequences reported in Romania among sporadic cases. The vaccination campaign resulted in 1136 people on 35 settlements receiving at least one dose of MMR vaccine and in the increase of one-dose MMR vaccine coverage at 24 months from 43% (23/53) to 91% (48/53). With measles transmission continuing in Europe, efforts must be made to meet immunization coverage targets, particularly in hard-to-reach communities where outbreaks may be difficult to control.


Subject(s)
Measles , Mumps , Roma , Rubella , Child , Humans , Disease Outbreaks , France/epidemiology , Measles/epidemiology , Measles/prevention & control , Measles-Mumps-Rubella Vaccine , Mumps/epidemiology , Rubella/epidemiology , Vaccination
2.
Arch Pediatr ; 28(4): 291-295, 2021 May.
Article in English | MEDLINE | ID: mdl-33773893

ABSTRACT

While enteroviruses (EV) are a well-recognized cause of aseptic meningitis in children, human parechoviruses (HPeV), especially genotype 3, have been increasingly reported as a frequent cause of sepsis-like illness and meningitis among young infants. The aim of this study was to describe the epidemiological, clinical, and laboratory characteristics of HPeV infections in infants and to compare them with those of well-known EV infections. This monocentric retrospective study was carried out at the pediatric unit of Nantes University Hospital from January 2015 to August 2018. All patients under 18 years of age with diagnosis codes referring to fever, for whom viral infection was suspected and cerebrospinal fluid (CSF) specimens were collected, were included. All CSF specimens were screened by duplex real-time polymerase chain reaction (PCR) assay that allows for the simultaneous detection of EV and HPeV in clinical samples. During the study period, 1373 CSF specimens from patients under 18 were included. A total of 312 CSF samples were positive for HPeV (n=34) or EV (n=278). Among the 34 HPeV-positive patients, 97% (33/34) were under 3 months of age, whereas the rate was 54% (149/278) for EV-positive patients (P<0.001); thus, patients under 3 months of age were defined as the study population for the rest of this work. A review of the medical records was carried out for the positive cases. In this population, the HPeV detection rate was 5.6% versus 25.3% (P<0.001) for EV. All but one of the HPeV samples available for genotyping were HPeV-3. No seasonality was observed for HPeV infections. Length of hospital stay tended to be longer for children infected with HPeV compared with those infected by EV (3 days vs. 2 days, P=0.05). Clinicians reported more severe illness presentations among HPeV-infected infants, with more frequent administration of fluid bolus (P<0.02). Regarding laboratory characteristics, a significant lack of cellular reaction in the CSF (P=0.004) as well as lower C-reactive protein (CRP) levels (P=0.006) and neutrophil counts (P<0.001) were noted for HPeV infections compared with EV infections. Our results confirm the early onset of HPeV infections (more than 95% of patients aged under 3 months). The clinical presentation and laboratory characteristics of the two infections was similar. However, some higher clinical severity criteria and a lack of CSF pleocytosis were regularly observed in patients with HPeV infections. Considering the significant proportion (5.6%; 95% CI, 3.7-7.5) of all CSF samples in our series, HPeV detection should be systematically included in the microbiological diagnosis of febrile children under 3 months of age.


Subject(s)
Enterovirus Infections/diagnosis , Enterovirus/isolation & purification , Parechovirus/isolation & purification , Picornaviridae Infections/diagnosis , Enterovirus/genetics , Enterovirus Infections/epidemiology , Female , France/epidemiology , Humans , Infant , Infant, Newborn , Length of Stay , Male , Parechovirus/genetics , Picornaviridae Infections/epidemiology , Polymerase Chain Reaction , Prevalence , Retrospective Studies , Sepsis/diagnosis
3.
Diagn Microbiol Infect Dis ; 85(3): 334-337, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27139081

ABSTRACT

We wanted to determine the diagnostic performance of a rapid influenza diagnostic test (RIDT) used bedside in a pediatric emergency department (PED). This was a prospective study over four consecutive winters (2009-2013), comparing the results of a RIDT (QuickVue®) with RT-PCR in children admitted to a PED. Among the 764 children included, we did not observe any significant differences in the diagnostic performance of RIDT except during the H1N1 pandemic. The overall sensitivity of the test was 0.82; the specificity 0.98; the positive and negative likelihood ratios 37.8 and 0.19. The positive and negative post-test probabilities of infection were 98% and 17%. The diagnostic performance was increased for influenza B cases (P = 0.03). RIDTs are suitable for use every winter with few differences in its diagnostic value, except during specific pandemic periods. This test could limit unnecessary complementary exams and guide the prescription of antivirals during influenza epidemic periods in PEDs.


Subject(s)
Diagnostic Tests, Routine/methods , Influenza, Human/diagnosis , Point-of-Care Systems , Adolescent , Child , Child, Preschool , Emergency Service, Hospital , Female , Humans , Infant , Infant, Newborn , Male , Predictive Value of Tests , Prospective Studies , Sensitivity and Specificity
4.
J Gynecol Obstet Biol Reprod (Paris) ; 45(9): 1115-1126, 2016 Nov.
Article in French | MEDLINE | ID: mdl-26907507

ABSTRACT

BACKGROUND: Cytomegalovirus (CMV) is the most frequent cause of congenital infection. The aim of this research was to describe the decision-process for parents to pursue gestation or to ask medical abortion after materno-fetal CMV infection. OBJECTIVES: The primary objective of this study is to analyze the decision-process for parents after materno-fetal infection with positive PCR after amniocentesis, to ask or not a medical termination of pregnancy (TOP). The secondary objectives are to compare ours results with literature review (pronostics factors, ultrasonographic signs and neonatal symptomatology). MATERIALS AND METHODS: This is a retrospective study, focused with a pluridisciplinary materno-fetal prenatal medical center, during a 14-year long period. Only 15 patients have been included in the study. They have been divided in 2 groups (the first group who decided to ask a TOP [n=8] and the second group who pursued the gestation [n=7]). We compare respectively their clinical, ultrasonographic, or other imagery and biological paths, before and after the birth. RESULTS: A total of 15/16 patients had a CMV seroconversion before 20weeks of gestation. The only infection after 20SA did not have any sequelae. The ultrasonography and the cerebral fetal MRI appeared to be very complementary for the assesment of brain injury, which is more frequent in the group with a TOP (7/8 versus 4/7). Three neonates out of 4 who had a cord positive viral blood load at birth are presenting neonatal symptoms, 2 of them will have severe brain and hearing injuries, the fourth one had no sequelae after 6months of life. CONCLUSION: Only the presence of ultrasonographic major brain damages, and confirmation with MRI, had a pejorative value as prognosis factor suggesting to patients to choose a TOP. Nevertheless, other ways of research are possible to assess the prognostic value in this difficult prenatal diagnosis process.


Subject(s)
Cytomegalovirus Infections/complications , Fetal Diseases/diagnostic imaging , Fetal Diseases/etiology , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious , Adult , Female , Humans , Pregnancy , Retrospective Studies , Ultrasonography, Prenatal
5.
Bone Marrow Transplant ; 47(2): 251-7, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21441959

ABSTRACT

This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first 6 months after UCBT, weekly all patients were DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. The cumulative incidences of EBV reactivation (defined as an EBV load >1000 EBV copies per 10(5) cells measured at least once during follow-up) at 6 months and 2 years after UCBT were 9 (95% confidence interval (CI), 2-22%) and 17% (95% CI, 6-33%), respectively. In 28 patients (85%), the EBV load remained negative at all times, and none of these patients experienced any sign of LPD. Five patients (15%) experienced at least one EBV reactivation episode. EBV reactivation was observed at a median of 132 days (range, 85-438) after UCBT. Two patients developed EBV-related LPD (cumulative incidence, 6% at 3 years). With a median follow-up of 468 days (range, 92-1277) post UCBT, the OS was 62% at 3 years. Five patients died of disease progression and seven patients died of transplant-related complications, including one case of EBV-related LPD. Univariate analysis did not identify any significant risk factor associated with EBV reactivation. We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life-threatening LPD.


Subject(s)
Cord Blood Stem Cell Transplantation/adverse effects , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/physiology , Transplantation Conditioning/adverse effects , Adolescent , Adult , Aged , Cord Blood Stem Cell Transplantation/methods , Epstein-Barr Virus Infections/drug therapy , Epstein-Barr Virus Infections/etiology , Epstein-Barr Virus Infections/immunology , Female , Hematologic Neoplasms/surgery , Hematologic Neoplasms/virology , Herpesvirus 4, Human/immunology , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Transplantation Conditioning/methods , Treatment Outcome , Virus Activation
7.
Leukemia ; 25(6): 932-8, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21350556

ABSTRACT

This single centre study assessed the incidence, kinetics and predictive factors of Epstein-Barr Virus (EBV) reactivation and EBV-related lymphoproliferative diseases (LPDs) in 175 consecutive patients who received a reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT). The cumulative incidence of EBV reactivation at 6 months after allo-HSCT defined as an EBV PCR load above 1000 copies of EBV DNA/10(5) cells was 15%, and none of these patients experienced any sign or symptom of LPD. A total of 17 patients, who had EBV DNA levels exceeding 1000 copies/10(5) cells on two or more occasions, were pre-emptively treated with rituximab. With a median follow-up of 655 (range, 92-1542) days post allo-HSCT, there was no statistically significant difference in term of outcome between those patients who experienced an EBV reactivation and those who did not. In multivariate analysis, the use of antithymocyte globulin as part of the RIC regimen was the only independent risk factor associated with EBV reactivation (relative risk=4.9; 95% confidence interval, 1.1-21.0; P=0.03). We conclude that patients undergoing RIC allo-HSCT using anti-thymocyte globulin as part of the preparative regimen are at higher risk for EBV reactivation. However, this did not impact on outcome, as quantitative monitoring of EBV viral load by PCR and preemptive rituximab therapy allowed for significantly reducing the risk of EBV-related LPD.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 4, Human/physiology , Transplantation Conditioning/adverse effects , Virus Activation/drug effects , Adolescent , Adult , Aged , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antilymphocyte Serum/adverse effects , Antilymphocyte Serum/therapeutic use , Antineoplastic Agents , Humans , Lymphoproliferative Disorders/virology , Middle Aged , Retrospective Studies , Rituximab , Transplantation Conditioning/methods , Viral Load/drug effects , Young Adult
8.
Bone Marrow Transplant ; 45(7): 1204-11, 2010 Jul.
Article in English | MEDLINE | ID: mdl-19935727

ABSTRACT

Occurrence of CMV, EBV and human herpes virus 6 (HHV6) infections and immune reconstitution were compared in 15 adult patients receiving a cord blood transplantation (CBT) and 40 patients who received an allogeneic transplantation from a matched unrelated donor (MUD). Herpes virus DNA quantifications in the blood (459 samples) were performed before and then monthly up to 9 months after transplant and the main lymphocytes populations were counted at 3, 6 and 9 months. Incidence of HHV6 infection was significantly higher in the CBT group (80 vs 42.5%; P<0.0001), with higher viral load (P<0.0001). In multivariate analysis, the use of a CBT and a myeloablative conditioning regimen were found to increase the risk of HHV6 infection (odds ratio (OR)=5.4, P=0.02 and OR=3.5, P=0.04, respectively). Incidences of CMV were similar between the two groups whereas MUD increased the risk of EBV infection, in univariate analysis only. HHV6 reactivation translated toward delayed neutrophils and plts engraftment in the two groups. MUD and CBT do not share the same immune reconstitution patterns, notably for B and CD8 lymphocytes and NK cells. There is a strong and specific relationship between HHV6 infection and the use of cord blood cells.


Subject(s)
Cord Blood Stem Cell Transplantation/adverse effects , Graft Survival/immunology , Hematopoiesis/immunology , Herpesvirus 6, Human , Myeloablative Agonists/toxicity , Roseolovirus Infections/etiology , Adult , Cytomegalovirus Infections/etiology , Epstein-Barr Virus Infections/etiology , Female , Humans , Incidence , Kinetics , Male , Middle Aged , Opportunistic Infections/etiology , Retrospective Studies , Tissue Donors , Viral Load , Virus Activation/drug effects , Young Adult
9.
Med Mal Infect ; 40(5): 296-8, 2010 May.
Article in French | MEDLINE | ID: mdl-19616908

ABSTRACT

BACKGROUND: Peripheral blood stem cell transplantation is a frequent option, especially for patients with hematological malignancies. CASE REPORTS: A first patient received this treatment for acute myeloblastic leukemia, the second for Richter's syndrome (follicular lymphoma). In both cases, allograft (unrelated donor, non myeloablative conditioning) was followed by graft versus host disease (GVH) requiring an immunosuppressive treatment. Respectively 15 and three months after graft, these two patients presented with multiple organ failure including very severe hepatic dysfunction. The diagnosis was made according to positive blood PCR, positive BAL, and hepatic histological findings. DISCUSSION: Adenoviruses, frequent in pediatrics, can be responsible for extremely severe infections among immunocompromised adults. T lymphocyte depletion plays a key role. CONCLUSION: Adenoviral infections can be fatal among immunocompromised patients. Diagnostic improvement should lead to early treatment, which however, remains to be clearly defined.


Subject(s)
Adenovirus Infections, Human , Multiple Organ Failure , Adenovirus Infections, Human/etiology , Adult , Humans , Immunocompromised Host , Male , Middle Aged , Multiple Organ Failure/etiology
11.
Am J Transplant ; 5(8): 1926-33, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15996241

ABSTRACT

BK virus (BKV) infection during the first year after renal transplantation was studied prospectively in 104 unselected consecutive patients. Viral DNA in urine (DNAuria) and plasma (DNAemia) samples was detected and quantified by real-time PCR. The noncoding control region (NCCR) of BKV isolates was sequenced. DNAuria and DNAemia occurred in 57% and 29% of patients, respectively. Three groups were defined, uninfected patients (group 1, n=45), patients with DNAuria (group 2, n=29) and patients with positive DNAemia (group 3, n=30). Active infection started within the first 3 months in 80% of patients. Cold ischemia duration over 24 h and the administration of tacrolimus were identified as significant risks factors for DNAuria, whereas it remains more frequently negative in patients receiving cyclosporine A. The risk for positive DNAemia was higher in patients with DNAuria (notably for viral load (VL)>4 log/mL) or treated with tacrolimus. No relationship was found with genetic variability in the NCCR sequence. Our data highlight the high frequency of active BKV infection after renal transplantation. Although high VL was detected in some patients, none developed a BKV nephropathy. A prospective follow-up of the whole population during the first year post renal transplantation is thus not useful to predict BKV disease.


Subject(s)
BK Virus/physiology , Kidney Diseases/virology , Kidney Transplantation , Polyomavirus Infections/virology , Tumor Virus Infections/virology , Base Sequence , Cyclosporine/therapeutic use , DNA, Viral/analysis , Female , Humans , Immunosuppressive Agents/therapeutic use , Kidney Diseases/therapy , Longitudinal Studies , Male , Middle Aged , Molecular Sequence Data , Prospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Nucleic Acid , Tacrolimus/therapeutic use , Viral Load , Virus Replication
13.
J Clin Microbiol ; 42(1): 242-9, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14715760

ABSTRACT

Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which is widely used. We deemed it essential to conduct a wide and coordinated survey of the emergence of ACV-resistant HSV strains. We have formed a network of 15 virology laboratories which have isolated and identified, between May 1999 and April 2002, HSV type 1 (HSV-1) and HSV-2 strains among hospitalized subjects. The sensitivity of each isolate to ACV was evaluated by a colorimetric test (C. Danve, F. Morfin, D. Thouvenot, and M. Aymard, J. Virol. Methods 105:207-217, 2002). During this study, 3900 isolated strains among 3357 patients were collected; 55% of the patients were immunocompetent. Only six immunocompetent patients excreted ACV-resistant HSV strains (0.32%), including one female patient not treated with ACV who was infected primary by an ACV-resistant strain. Among the 54 immunocompromised patients from whom ACV-resistant HSV strains were isolated (3.5%), the bone marrow transplantation patients showed the highest prevalence of resistance (10.9%), whereas among patients infected by human immunodeficiency virus, the prevalence was 4.2%. In 38% of the cases, the patients who excreted the ACV-resistant strains were treated with foscarnet (PFA), and 61% of them developed resistance to PFA. The collection of a large number of isolates enabled an evaluation of the prevalence of resistance of HSV strains to antiviral drugs to be made. This prevalence has remained stable over the last 10 years, as much among immunocompetent patients as among immunocompromised patients.


Subject(s)
Acyclovir/pharmacology , Antiviral Agents/pharmacology , Simplexvirus/drug effects , Adult , Aged , Aged, 80 and over , Animals , Bone Marrow Transplantation , Chlorocebus aethiops , Drug Resistance, Viral , Female , Humans , Male , Middle Aged , Organ Transplantation , Vero Cells
14.
Eur J Clin Microbiol Infect Dis ; 21(7): 532-6, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12172744

ABSTRACT

A quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method based on TaqMan technology was developed to determine the presence and amount of enterovirus RNA. In order to prevent false-negative results, a one-step multiplex RT-PCR was optimized. It contains two dual-labelled fluorogenic probes to quantify the 5' noncoding region of enterovirus and detect an internal positive control. In the present study, 104 cerebrospinal fluid samples collected during an outbreak of enteroviral meningitis were analyzed using this method. Amplification of the internal positive control was effective in all but two specimens, confirming the absence of PCR inhibitors and allowing the results of amplification to be validated. The sensitivity of the RT-PCR was 96.8%, while that of cell culture was 34.9%. Genomic viral loads found ranged between 3.3 and 5.9 log(10) copies per milliliter of cerebrospinal fluid (mean, 4.8 log(10) copies/ml). This fluorogenic enterovirus RT-PCR allows large numbers of samples to be screened rapidly. Moreover, its sensitivity and reproducibility make it highly reliable. With these characteristics, the enterovirus RT-PCR can be a useful tool that may offer considerable benefit in the clinical management of patients with enteroviral infections.


Subject(s)
Enterovirus Infections/cerebrospinal fluid , Enterovirus Infections/diagnosis , Enterovirus/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction/methods , Reverse Transcriptase Polymerase Chain Reaction/standards , Adolescent , Adult , Child , Child, Preschool , Disease Outbreaks , Enterovirus/genetics , Enterovirus Infections/epidemiology , Enterovirus Infections/virology , False Negative Reactions , Female , France/epidemiology , Humans , Infant , Infant, Newborn , Male , Meningitis, Viral/cerebrospinal fluid , Meningitis, Viral/diagnosis , Meningitis, Viral/epidemiology , Meningitis, Viral/virology , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Viral Load , Virus Cultivation
15.
Clin Diagn Lab Immunol ; 7(2): 206-11, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10702494

ABSTRACT

A technique was developed with flow cytometry to quantify the two immediate-early proteins ZEBRA and Rta, which are involved in the activation of Epstein-Barr virus replication. We evaluated four monoclonal antibodies on four cell lines (B95-8, RAJI, Namalwa, and P3HR1) with varying levels of expression of these replication-phase antigens. The Namalwa lymphoma cell line was used as a negative control. Four fixation-permeabilization procedures were compared. The preparation of cells with paraformaldehyde and methanol in sequence, and antigen detection with AZ125 and AR 5A9 monoclonal antibodies, were found to be the optimal conditions in these cell lines. Our procedure allowed ZEBRA antigen to be detected in 4.85% of peripheral blood mononuclear cells from a transplant recipient with a lymphoproliferative disease.


Subject(s)
DNA-Binding Proteins/analysis , Fixatives , Formaldehyde , Herpesvirus 4, Human , Immediate-Early Proteins/analysis , Methanol , Polymers , Trans-Activators/analysis , Viral Proteins/analysis , Animals , DNA-Binding Proteins/immunology , Flow Cytometry/methods , Immediate-Early Proteins/immunology , Mice , Mice, Inbred BALB C , Trans-Activators/immunology , Tumor Cells, Cultured , Viral Proteins/immunology
16.
Bone Marrow Transplant ; 23(6): 629-30, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10217196

ABSTRACT

There is a growing interest in the evaluation of non-myeloablative conditioning therapy for allogeneic stem cell transplantation. Such regimens are expected to produce less toxicity while allowing both engraftment and a graft-versus-disease effect from the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. Heavy immunosuppression used in recipients may have unexpected consequences. We describe the occurrence of a fatal Epstein-Barr virus-associated B cell lymphoproliferative disease (BLPD) early after such a non-myeloablated allogeneic peripheral blood stem cell transplant in a heavily pretreated patient.


Subject(s)
Epstein-Barr Virus Infections/complications , Hematopoietic Stem Cell Transplantation , Lymphoproliferative Disorders/etiology , Transplantation Conditioning , Adult , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Lymphoproliferative Disorders/virology , Myeloablative Agonists/therapeutic use , Transplantation, Homologous
17.
Ann Intern Med ; 129(3): 182-9, 1998 Aug 01.
Article in English | MEDLINE | ID: mdl-9696725

ABSTRACT

BACKGROUND: Acinetobacter baumannii is an important opportunistic pathogen that is rapidly evolving toward multidrug resistance and is involved in various nosocomial infections that are often severe. It is difficult to prevent A. baumannii infection because A. baumannii is ubiquitous and the epidemiology of the infections it causes is complex. OBJECTIVE: To study the epidemiology of A. baumannii infections and assess the relation between fluoroquinolone use and the persistence of multidrug-resistant clones. DESIGN: Three case-control studies and a retrospective cohort study. SETTING: A 20-bed medical and surgical intensive care unit. PATIENTS: Acinetobacter baumannii was isolated from 45 patients in urine (31%), the lower respiratory tract (26.7%), wounds (17.8%), blood (11.1%), skin (6.7%), cerebrospinal fluid (4.4%), and sinus specimens (2.2%). One death was due to A. baumannii infection. MEASUREMENTS: Antimicrobial resistance pattern and molecular typing were used to characterize isolates. The incidence of A. baumannii infection and the use of fluoroquinolones were calculated annually. RESULTS: Initially, 28 patients developed A. baumannii infection. Eleven isolates had the same antimicrobial susceptibility profile, genotypic profile, or both (epidemic cases), and 17 were heterogeneous (endemic cases). A surgical procedure done in an emergency operating room was the main risk factor for epidemic cases, whereas previous receipt of a fluoroquinolone was the only risk factor for endemic cases. The opening of a new operating room combined with the restriction of fluoroquinolone use contributed to a transitory reduction in the incidence of infection. When a third epidemiologic study was done, previous receipt of a fluoroquinolone was again an independent risk factor and a parallel was seen between the amount of intravenous fluoroquinolones prescribed and the incidence of endemic infection. CONCLUSION: Epidemic infections coexisted with endemic infections favored by the selection pressure of intravenous fluoroquinolones.


Subject(s)
Acinetobacter Infections/epidemiology , Acinetobacter Infections/microbiology , Acinetobacter/drug effects , Anti-Infective Agents/pharmacology , Cross Infection/epidemiology , Cross Infection/microbiology , Acinetobacter/classification , Acinetobacter/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Drug Resistance, Multiple , Female , Fluoroquinolones , Humans , Male , Middle Aged , Opportunistic Infections/epidemiology , Opportunistic Infections/microbiology , Retrospective Studies
18.
J Clin Microbiol ; 35(10): 2665-9, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9316930

ABSTRACT

Cytomegalovirus (CMV) antigenemia was directly detected in polymorphonuclear leukocytes (PMNLs) from transplant recipients by using flow cytometry (FC). Two fixation and permeabilization methods and seven anti-CMV monoclonal antibodies (MAbs) were evaluated. 1C3, SL20, and NEA-9221 MAbs were more efficacious. The antigenemia detection threshold of FC was 0.05% positive PMNLs, and percentages correlated well with DNA viral load and the appearance of clinical symptoms.


Subject(s)
Antigens, Viral/blood , Cytomegalovirus Infections/diagnosis , Flow Cytometry/methods , Neutrophils/virology , Antibodies, Monoclonal , Antibodies, Viral , Bone Marrow Transplantation/adverse effects , Evaluation Studies as Topic , Fluorescent Antibody Technique , Humans , Kidney Transplantation/adverse effects , Permeability , Reproducibility of Results , Time Factors , Tissue Fixation
19.
Bone Marrow Transplant ; 15(4): 611-7, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7655389

ABSTRACT

The aim of this prospective study of 162 recipients of bone marrow transplantation (BMT) was to evaluate the use of DNAemia detection by semi-nested PCR for the diagnosis of human cytomegalovirus (HCMV) infection and HCMV disease. We compared the results obtained for DNAemia with those obtained for viremia, using the shell vial assay. Patients were divided in three groups, according to BMT type (allogeneic or autologous) and date of transplant; 876 DNAemia/viremia pairs were analyzed and the overall concordance between the two tests was 97.5%. Discrepancies between the two tests were essentially due to the earlier positivity of DNAemia. Among the 10 patients with positive DNAemia episodes, 9 developed HCMV disease. DNAemia was more sensitive than viremia for HCMV disease diagnosis, while viremia had a higher positive predictive value. DNAemia appeared easily adaptable to routine laboratory use, less expensive and more informative than viremia. This study shows that DNAemia is a method that can replace viremia detection, allowing HCMV infection and disease follow-up of recipients of allogeneic BMT during the first year after BMT.


Subject(s)
Bone Marrow Transplantation , Cytomegalovirus Infections/diagnosis , Cytomegalovirus/isolation & purification , DNA, Viral/blood , Polymerase Chain Reaction/methods , Viremia/diagnosis , Adolescent , Adult , Diagnosis, Differential , Follow-Up Studies , Humans , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Transplantation, Autologous , Transplantation, Homologous
20.
Eur J Obstet Gynecol Reprod Biol ; 52(3): 193-200, 1993 Dec 30.
Article in English | MEDLINE | ID: mdl-8163035

ABSTRACT

Polymerase chain reaction (PCR) was used to identify human papillomavirus (HPV) in 216 cervical biopsy specimens from women referred to the gynecological out-patient unit for colposcopy because of an abnormal smear. HPV DNA was screened using type-specific primers for HPV6, 11, 16, 18, 31 and 33 (TS-PCR) as well as a consensus primer located in the E1 region of the HPV genome (C-PCR). TS-PCR specificity was validated by Southern blot analysis. Low-grade (SIL 1) and high-grade (SIL 2) squamous intraepithelial lesions were found in 165 biopsies. HPV16 detection was better with PCR than Southern blot, particularly for SIL 1 and SIL 2. The fact that 10% of HPV16 (all SIL 2) were not detected by C-PCR indicates that both PCR techniques should be performed. C-PCR also detects uncharacterized HPV types (8.6% prevalence in our results), mainly in SIL 1 and SIL 2. HPV16, the most frequently isolated type (prevalence 21%), was associated with SIL 2 in 83% of cases. A low HPV prevalence was found in specimens without dysplastic cells. These results suggest that PCR may be an important tool for identifying women at risk for developing dysplasia or cervical cancer.


Subject(s)
Cervix Uteri/microbiology , Papillomaviridae/isolation & purification , Polymerase Chain Reaction/methods , Uterine Cervical Dysplasia/microbiology , Adult , Blotting, Southern , Female , Humans , Papillomaviridae/genetics , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...